INTRODUCTION AND OBJECTIVES: While the value of MRI-US Fusion-targeted biopsy (MRF-TB) in the identification of occult, clinically significant prostate cancer (csPCa), has been well described, the accuracy of targeting using available fusion platforms is not as clear. As the need for repeat biopsy among men with negative or low risk MRF-TB remains to be defined, we evaluated the outcomes of repeat MRF-TB among men with initially negative or low risk MRF-TB.
METHODS: Between 6/2012 and 9/2016, 1,584 consecutive men undergoing pre-biopsy prostate MRI followed by MRF-TB and systematic biopsy (SB) were enrolled in prospective date registry. 195 men underwent repeat MRI and MRF-TB for continued suspicion of csPCa. 76 men were excluded from analysis due to outside facility or 1.5T MRI, hip implant or interval focal therapy. Upgrade was defined as an increase in Gleason score (GS) from 3+3 to !3+4 or from 3+4 to !4+3 among men with PCa noted on first MRF-TB, or any cancer among men with no cancer on first MRF-TB. Biopsy outcomes were stratified per MRI findings and progression.
RESULTS: 119 men (mean age 65.9AE7.7 years, mean PSA 5.8AE4.5 ng/mL) underwent repeat MRF-TB. The median interval between initial and repeat biopsy was 17.1AE8.9 months. On repeat biopsy, 50% (59) had concordant GS, 17% (20) were downgraded, and 34% (40) were upgraded. Of the 40 upgrades, 42% (17) were due to an increase in GS and 58% (23) were due to newly detected PCa, as illustrated in Table 1 . PI-RADS score was predictive of the likelihood of upgrade on repeat MRF-TB ( Table 2) . 53% of men with PI-RADS 4 and 5 demonstrated upgrade on repeat biopsy compared to 26% of men with PI-RADS 3. 82% (9/11) of upgrades in men with PI-RADS 1 and 2 were due to newly detected GS 6 disease.
CONCLUSIONS: 53% of men with PI-RADS 4 and 5 lesions were upgraded on repeat MRF-TB, suggesting a need for repeat sampling among men with low risk or negative MRF-TB and persistent PI-RADS 4 and 5 regions noted on follow-up MRI. Among men with PI-RADS 1 or 2 on repeat imaging, continued observation may be reasonable given the low likelihood (5%) of csPCa on repeat MRF-TB. inter-reader agreement and diagnostic performance of qualitative descriptors versus a 5-point Likert scale for determination of EPE. METHODS: This was an IRB-approved, HIPAA-compliant, single-center, retrospective study with 3 experienced and 2 non-experienced readers. Men who underwent mpMRI of the prostate followed by radical prostatectomy between Nov/2015 and Jul/2016 were eligible. Whole-mount prostatectomy specimen processed with a 3D-printed, patient-specific mold for precise anatomical registration was the standard of reference. Reviewers chose one or more of 8 qualitative descriptors (e.g., capsular bulging, irregular margin) and, after a washout period, assigned a Likert score for the likelihood of EPE: 1, highly unlikely; 2, unlikely; 3, indeterminate; 4, likely; 5, highly likely. Reproducibility among reviewers was assessed with weighted kappa statistics (<0,no agreement; 0-0.20 slight, 0.21-0.40 fair, 0.41-0.60 moderate, 0.61-0.80 substantial, and 0.811 almost perfect). Cochran-Armitage Trend test was used to test the association bewteen pathology-proven EPE and MRI-based Likert score.
Source of
RESULTS: Eighty men met eligibility criteria; mean age: 64 years, PSA: 8.0 ng/mL; prostate volume: 39.9 cc; Histologic index lesion size: 22AE9 mm; Gleason score 3+4, 62.5%; !4+3, 37.5%. EPE was present in 40(50%) men. Qualitative descriptors had inconsistent reproducibility (kappa as low as 0.33 for experienced and -0.02 for inexperienced readers) and poor accuracy (as low as 0.41). Agreement was moderate for experienced (k¼0.56) and non-experienced (0.46) readers with the Likert scale. There was significant increase in the likelihood of EPE with higher Likert scores (Figure 1) .
CONCLUSIONS: A 5-point Likert scale improves inter-reader reproducibility and the diagnostic performance of mpMRI compared to qualitative descriptors of EPE, facilitating informed decision making, treatment planning and patient counseling. 
Source of Funding: This investigation was supported by the

INTRODUCTION AND OBJECTIVES:
We investigated the accuracy of multi-parametric MRI (mpMRI) for preoperative staging and its influence on the determination of neurovascular bundle sparing and disease prognosis in patients with localized prostate cancer.
METHODS: We reviewed 1,045 patients who underwent radical prostatectomy with preoperative mpMRI at a single institution. Clinical local stages determined from mpMRI were correlated with preoperative and postoperative pathological outcomes.
RESULTS:
The sensitivity and specificity to diagnose seminal vesicle invasion (SVI) on mpMRI were 43.8% and 95.4%, respectively. The negative predictive value was 78.9%. The sensitivity and specificity to diagnose extracapsular invasion (ECE) were 54.5% and 80.5%, respectively. The overall sensitivity and specificity of diagnosing pathological T3 or higher were 52.6% and 82.1%, respectively. Non-organconfined disease determined by mpMRI was significantly associated with positive surgical margin and pathological T3 disease on multivariate analysis. Preoperative adverse findings on mpMRI were significantly associated with performance of the non-nerve-sparing technique.
CONCLUSIONS: The mpMRI did not show outstanding diagnostic accuracy relative to our expectations in predicting SVI or ECE preoperatively. However, adverse findings on preoperative mpMRI were significantly related with worse postoperative pathological outcomes as well as postoperative biochemical recurrence.
Source of Funding: None
PD61-08 DOES GLEASON SCORE AT THE SITE OF POSITIVE SURGICAL MARGIN PREDICT RECURRENCE FOLLOWING RADICAL PROSTATECTOMY?
Goran Rac*, Lawrence Dagrosa, Laura Spruill, Thomas Keane, Charleston, SC INTRODUCTION AND OBJECTIVES: Multiple pathologic features have been shown to predict biochemical recurrence (BCR) in patients after radical prostatectomy (RP) for prostate cancer. While positive surgical margins (PSM) have been shown to increase the likelihood of BCR, little data exists on the clinical significance of the tumor Gleason grade at the site of PSM. This study aims to assess if the Gleason grade at the PSM is predictive of BCR, and whether its predictive value differs from that of other commonly referenced risk factors.
METHODS: We performed a retrospective review of a prospectively maintained database of all patients who underwent RP at our institution from 2009 to 2015. We identified 403 patients, 58 (14.4%) of whom were noted to have PSM. These cases were reviewed by an attending Pathologist who assigned a Gleason grade (3, 4 or 5) to the tumor at the site of PSM. The predictive value for BCR was compared to that of final pathology Gleason score and presence of PSM alone.
RESULTS: We found that 34.5% (20/58) of patients with PSM had BCR, which was greater than the overall BCR rate of 19.9% (80/ 403) (p < 0.0001). Patients with Gleason 4+ disease at the PSM had a higher BCR rate (57.9%, 11/19) compared to those with Gleason 3 (23.1%, 9/39, p ¼ 0.009) and those with a negative margin (17.4%, 60/ 345, p < 0.0001). Interestingly, patients with Gleason 3 at the PSM did not have a significantly higher BCR rate than those with a negative e1190 THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Monday, May 15, 2017 
